Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

VERABullishIndustry Newsnews

High materiality8/10

Vera Therapeutics confirms strong ORIGIN 3 results for IgA nephropathy

Sep 15, 2026, 1:25 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive efficacy signals and durability data can lift expectations for approval timing and long-term value, though actual market impact depends on regulatory outcomes and durability beyond 104 weeks.

AI summary

What happened, with direct paths to the underlying reporting

Vera Therapeutics announced final ORIGIN 3 results for Trutakna in IgA nephropathy, meeting prespecified endpoints. The 428-patient trial shows eGFR stabilization and a 76% reduction in composite kidney disease progression through 104 weeks, with no dialysis or kidney-related death in treated patients. The data could bolster the case for later-stage development and potential approval signals.

ORIGIN 3 met endpoints; 428 patients analyzed.
At 52 weeks, eGFR change: -0.1 vs -5.7 with placebo.
104 weeks: eGFR slope -0.6 vs -5.6; 76% risk reduction.
No dialysis/kidney death in Trutakna group through 104 weeks.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.